Patients with stage III or IV melanoma who have not received treatment with BRAF inhibitors remain at risk for developing new primary melanomas, although the incidence rates are lower than those observed in studies of dabrafenib and vemurafenib, according to research published online Dec. 2 in the Journal of Clinical Oncology.
MRV Research
ZIOPHARM Reports Positive Interim Results in Patients With Advanced Melanoma From Ongoing Phase 1/2 Study of Ad-RTS-IL-12
ZIOPHARM Oncology, Inc. ZIOP +2.07% today announced positive interim results from its ongoing Phase 1/2 study of Ad-RTS-IL-12, a novel DNA-based therapeutic candidate that is being evaluated with the oral activator, veledimex, in patients with advanced melanoma. The results from this multicenter study were presented at Melanoma Bridge 2013 Conference at the session “Best Abstracts on News in Immunotherapy", an international conference co-sponsored by Istituto Nazionale Tumori Fondazione, Sidra Medical and Research Center, and the Society for ImmunoTherapy of Cancer that is being held in Naples, Italy.
Nivolumab induced responses in melanoma refractory or naive to ipilimumab
Patients with ipilimumab-refractory or ipilimumab-naive melanoma demonstrated response to nivolumab with or without a peptide vaccine, according to study results.
Melanoma risk linked with IVF treatment and birth
AN INVESTIGATION into the association between IVF treatment and melanoma found women who had IVF treatment and gave birth to one or two children had an increased rate of invasive melanoma compared with those who did not have children.